annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
1:15 PM - 2:30 PM
EDUCATION SESSIONS
Combined Modalities in Pancreatic Cancer: Should Recent Trials Change Our
Practice?
Location: N Hall B1
CME credit: 1.25
Track(s): Gastrointestinal (Noncolorectal) Cancer; Developmental Therapeutics
David Linehan, MD—Chair
Washington University School of Medicine
Surgical Approach in Resectable and Borderline Resectable Pancreatic Cancer
Gauri R. Varadhachary, MD
University of Texas M. D. Anderson Cancer Center
The Role of Neoadjuvant versus Adjuvant Chemotherapy in Pancreatic Cancer: What Does the
Data Tell Us?
Theodore Steven Lawrence, MD, PhD
University of Michigan
Role of Radiation in Locally Advanced Pancreatic Cancer
Complications of Myeloma and Myeloma Therapies
Location: E354a
CME credit: 1.25
Track(s): Lymphoma and Plasma Cell Disorders; Patient and Survivor Care
Todd M. Zimmerman, MD—Chair
The University of Chicago
Prophylaxis of Venous Thromboembolic Disease Associated with Immunomodulatory Agents
Paul Gerard Guy Richardson, MD
Dana-Farber Cancer Institute
Prevention and Management of Treatment-induced Peripheral Neuropathy
G. David Roodman, MD, PhD
University of Pittsburgh
Myeloma Bone Disease: What’s New?
Controversies in the Management of Metastatic Breast Cancer
Location: E Hall D1
CME credit: 1.25
Track(s): Breast Cancer; Professional Development
Cliff Hudis, MD—Chair
Memorial Sloan-Kettering Cancer Center
Integration and Sequence of Systemic Options: How to Translate Clinical Trial Results into
Routine Practice?
Jonas Bergh, MD, PhD
Karolinska University Hospital
Biological Evolution of Breast Cancer: Should a Metastasis Be Rebiopsed?
Michael J. Hassett, MD, MPH
Dana-Farber Cancer Institute
Should Cost Be a Consideration in the Management of Metastatic Breast Cancer?
388